Sumatriptan
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Sumatriptan
Sumatriptan: Known uses and market status in Australia
Summary
The TxGNN model’s candidates for Sumatriptan were all traced to known uses, so there is currently no new predicted indication. The one known use found among the candidates is migraine with brainstem aura, which is supported by a licence in another country.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| migraine with brainstem aura | licence in another country (approved indication: migraine) |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10694W | Imigran FDT | Tablet (fast disintegrating) 50 mg (as s | Valid |
Safety Considerations
Contraindications suggested by the knowledge graph (these are graph-derived associations, not label text):
- Cardiovascular and cerebrovascular: coronary artery disease, myocardial infarction, congestive heart failure, heart disease, cardiovascular disease, peripheral vascular disease, stroke, cerebral infarction, cerebrovascular disorder, hypertension
- Hepatic and renal: liver disease, liver failure, kidney disease
- Other: epilepsy, diabetes mellitus, diabetic ketoacidosis, substance abuse/dependence, blood coagulation disease, obesity, gallbladder disease, haemoglobinopathy and anaemia
Drug interactions (100 recorded; main ones listed):
- Major: dexfenfluramine, fenfluramine, lorcaserin, sibutramine (serotonergic agents), and 5-HT3 antagonists dolasetron, granisetron, ondansetron, palonosetron
- Moderate: morphine (including liposomal)
Other recorded interactions have unknown severity.
Other points from the literature and trial data: medication-overuse headache risk, and the theoretical vasoconstriction concern in brainstem aura. Please refer to the TGA-approved Product Information (PI) for full warnings and contraindications.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.